Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures

Overview

Journal Rambam Maimonides Med J

Specialty General Medicine

Date 2022 Jun 14

PMID 35701156

Authors

Cenk Aypak

Mustafa A Bircan

Ayse Ozdemir

Affiliations

Soon will be listed here.

Abstract

Objectives: Anti-osteoporotic drugs (AOD) are essential for secondary prevention of osteoporotic fracture (OF) in patients with established osteoporosis. However, data about AOD utilization rates are scarce among patients with OF. This study was therefore aimed at determining the AOD utilization rates among those particularly vulnerable patients.

Materials And Methods: This cross-sectional study followed the medical records of patients with OF starting from their first OF diagnosis date. Each patient's preventive osteoporosis treatments (vitamin D, calcium+vitamin D) and AOD utilization rate were recorded for a 12-month period following OF diagnosis.

Results: A total of 210 patients (168 females, mean age: 67.8±11.9 years; 42 males, mean age 62.4±16.1 years) were enrolled in the study. Of these, 65.7% (n=138) did not use any medication for primary protection against osteoporosis before OF diagnosis. The ratio of patients not using any type of medication for secondary prevention after OF increased from 26.5% to 51% during a 12-month period. In addition, by one year following diagnosis, AOD usage rate had decreased from 62.3% to 41.3%.

Conclusion: The AOD usage rates for secondary prevention of OF were insufficient, and cessation rates were high. Identification of factors associated with decreased AOD utility rates will provide important information for guiding patient follow-up in order to reduce the occurrence of OF.

Citing Articles

Effect of Lifestyle Modification Intervention Programme on Bone Mineral Density among Postmenopausal Women with Osteoporosis.

Anupama D, Noronha J, Acharya K, Prabhu M, Ravishankar N, Nayak B Sultan Qaboos Univ Med J. 2023; 23(3):387-393.

PMID: 37655089 PMC: 10467558. DOI: 10.18295/squmj.1.2023.010.

Secondary Prevention of Osteoporosis: If Not Now, When?.

Dwolatzky T Rambam Maimonides Med J. 2022; 13(3).

PMID: 35921486 PMC: 9345767. DOI: 10.5041/RMMJ.10478.

References

Wilk A, Sajjan S, Modi A, Fan C, Mavros P . Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int. 2014; 25(12):2777-86. PMC: 4221620. DOI: 10.1007/s00198-014-2827-x. View

Siris E, Modi A, Tang J, Gandhi S, Sen S . Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Curr Med Res Opin. 2013; 30(1):123-30. DOI: 10.1185/03007995.2013.851074. View

Gillespie C, Morin P . Osteoporosis-Related Health Services Utilization Following First Hip Fracture Among a Cohort of Privately-Insured Women in the United States, 2008-2014: An Observational Study. J Bone Miner Res. 2017; 32(5):1052-1061. DOI: 10.1002/jbmr.3079. View

Guggenbuhl P . Osteoporosis in males and females: Is there really a difference?. Joint Bone Spine. 2009; 76(6):595-601. DOI: 10.1016/j.jbspin.2009.10.001. View

Eastell R, ONeill T, Hofbauer L, Langdahl B, Reid I, Gold D . Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016; 2:16069. DOI: 10.1038/nrdp.2016.69. View

Kung A, Fan T, Xu L, Xia W, Park I, Kim H . Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health. 2013; 13:7. PMC: 3637813. DOI: 10.1186/1472-6874-13-7. View

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Hopkins R, Goeree R, Pullenayegum E, Adachi J, Papaioannou A, Xie F . The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord. 2011; 12:209. PMC: 3196921. DOI: 10.1186/1471-2474-12-209. View

Dreinhofer K, Anderson M, Feron J, Herrera A, Hube R, Johnell O . Multinational survey of osteoporotic fracture management. Osteoporos Int. 2004; 16 Suppl 2:S44-53. DOI: 10.1007/s00198-004-1700-8. View

10.

Kim S, Ha Y, Park Y, Lee S, Koo K . Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study. J Korean Med Sci. 2011; 26(11):1501-7. PMC: 3207055. DOI: 10.3346/jkms.2011.26.11.1501. View

11.

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

12.

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

13.

Chau Y, Nashi N, Law L, Goh R, Choo S, Seetharaman S . Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore. Arch Osteoporos. 2020; 15(1):141. DOI: 10.1007/s11657-020-00816-2. View

14.

Luthje P, Nurmi-Luthje I, Kaukonen J, Kuurne S, Naboulsi H, Kataja M . Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr. 2008; 49(1):153-7. DOI: 10.1016/j.archger.2008.06.007. View

15.

Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X . Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int. 2017; 28(8):2485-2494. PMC: 5524851. DOI: 10.1007/s00198-017-4072-6. View

16.

Reyes C, Tebe C, Martinez-Laguna D, Ali M, Soria-Castro A, Carbonell C . One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017; 28(10):2997-3004. DOI: 10.1007/s00198-017-4144-7. View

17.

Klop C, Gibson-Smith D, Elders P, Welsing P, Leufkens H, Harvey N . Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Osteoporos Int. 2015; 26(7):1919-28. PMC: 4483189. DOI: 10.1007/s00198-015-3098-x. View

18.

Giusti A, Barone A, Razzano M, Oliveri M, Pizzonia M, Palummeri E . Persistence with calcium and vitamin D in elderly patients after hip fracture. J Bone Miner Metab. 2008; 27(1):95-100. DOI: 10.1007/s00774-008-0007-9. View

19.

Mirza F, Canalis E . Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015; 173(3):R131-51. PMC: 4534332. DOI: 10.1530/EJE-15-0118. View

20.

Thong B, Ima-Nirwana S, Chin K . Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. Int J Environ Res Public Health. 2019; 16(9). PMC: 6540255. DOI: 10.3390/ijerph16091571. View